Scarica l'app Stockscreener
1.26
6.67%
-0.09
Dopo l'orario di chiusura:
1.31
0.05
+3.97%
Precedente Chiudi:
$1.35
Aprire:
$1.37
Volume 24 ore:
122.02K
Relative Volume:
0.70
Capitalizzazione di mercato:
$20.26M
Reddito:
-
Utile/perdita netta:
$-15.31M
Rapporto P/E:
-0.7849
EPS:
-1.6054
Flusso di cassa netto:
$-15.08M
1 W Prestazione:
+1.61%
1M Prestazione:
+49.09%
6M Prestazione:
-24.10%
1 anno Prestazione:
+39.55%
Intervallo 1D:
$1.25
$1.37
Intervallo di 1 settimana:
$1.195
$1.415
Portata 52W:
$0.6138
$2.35
Allarity Therapeutics Inc Stock (ALLR) Company Profile
Nome
Allarity Therapeutics Inc
Settore
Industria
Telefono
401-426-4664
Indirizzo
24 SCHOOL ST., 2ND FLOOR, BOSTON
Compare ALLR vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ALLR
Allarity Therapeutics Inc
|
1.26 | 20.26M | 0 | -15.31M | -15.08M | -1.6054 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.34 | 119.23B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.77 | 78.84B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
700.45 | 43.35B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.41 | 41.57B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.05 | 31.51B | 5.36B | 287.73M | 924.18M | 2.5229 |
Allarity Therapeutics Inc Stock (ALLR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-28 | Iniziato | Ascendiant Capital Markets | Buy |
Allarity Therapeutics Inc Borsa (ALLR) Ultime notizie
Allarity’s Terminated Breast Cancer Trial Signals Setback for DRP-Guided Chemotherapy - TipRanks
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates - GuruFocus
Big Picture: Is Allarity Therapeutics Inc backed by strong institutional buying2026 Momentum Check & Community Verified Watchlist Alerts - baoquankhu1.vn
Allarity Therapeutics Secures $20 Million Debt Financing to Advance Stenoparib Toward FDA Approval and Extend Cash Runway to 2028 - Minichart
Allarity closes $20M non-convertible debt to fund stenoparib Phase 2 and extend runway - TradingView
Allarity Therapeutics (NASDAQ: ALLR) closes $20M debt to fund trials - Stock Titan
Allarity closes $20M financing for stenoparib advancement - Yahoo Finance
Allarity secures $20M debt financing to extend cash runway - Investing.com South Africa
Allarity Therapeutics, Inc. announced that it has received $20.93 million in funding - marketscreener.com
Allarity Therapeutics, Inc. Closes $20 Million Non-Convertible Debt Financing - marketscreener.com
Allarity Therapeutics Secures $20 Million Structured Note Financing - TipRanks
Allarity Therapeutics Secures $20.9M Notes Financing From Streeterville, With Collateral Agreements - TradingView
Allarity Therapeutics closes $20 million financing to accelerate the advance of stenoparib toward FDA approval and commercialization - marketscreener.com
Allarity Therapeutics (ALLR) enters $20.93M secured note deal with covenants - Stock Titan
Allarity Therapeutics Closes $20 Million Financing to Accelerate the Advance of Stenoparib ... - Bluefield Daily Telegraph
Allarity Therapeutics Closes $20 Million Financing To Accelerate The Advance Of Stenoparib Toward FDA Approval And Commercialization - TradingView
Allarity Therapeutics Closes $20 Million Financing to - GlobeNewswire
Ovarian cancer drug keeping patients 30+ months gets $20M boost - Stock Titan
Aug Analyst Calls: What is Allarity Therapeutics Incs 5 year growth outlookJuly 2025 Short Interest & Free Real-Time Market Sentiment Alerts - baoquankhu1.vn
Retail Trends: What are REV Group Incs earnings expectationsJuly 2025 Chart Watch & Real-Time Stock Entry Alerts - baoquankhu1.vn
ALLR Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Allarity Therapeutics doses first patients in VA-funded small cell lung cancer trial - Mugglehead Investment Magazine
Why analysts upgrade Allarity Therapeutics Inc. stockRate Hike & Real-Time Buy Zone Alerts - mfd.ru
Allarity Therapeutics doses first patients in VA-funded Phase 2 SCLC trial - TradingView
VA-funded Phase 2 stenoparib trial begins for Allarity (NASDAQ: ALLR) - Stock Titan
First patients dosed in VA-funded stenoparib trial for lung cancer - Investing.com Australia
Allarity Therapeutics Doses First Patients in Phase 2 Lung Cancer Trial - marketscreener.com
Allarity Therapeutics Doses First Patients in VA-Funded Phase 2 Trial Focused on Small Cell Lung Cancer with High Unmet Need - The Manila Times
Allarity Therapeutics Initiates VA-Funded Phase 2 Trial of Stenoparib and Temozolomide for Relapsed Small Cell Lung Cancer - Quiver Quantitative
What is Allarity Therapeutics Inc. s 5 year growth outlook2025 Key Lessons & Detailed Earnings Play Strategies - mfd.ru
Why Allarity Therapeutics Inc. stock remains on buy listsWeekly Profit Report & Real-Time Volume Analysis - mfd.ru
Resistance Check: Is Allarity Therapeutics Inc stock good for income investorsJuly 2025 Price Swings & Reliable Trade Execution Plans - baoquankhu1.vn
Biotechnology company Allarity Therapeutics Inc recently filed documents with the U.S. Securities and Exchange Commission, disclosing that its selling shareholders plan to resell 255,103 shares of the company’s common stock. - Bitget
Value Recap: What is the next catalyst for Allarity Therapeutics IncTrade Risk Summary & Risk Controlled Stock Alerts - baoquankhu1.vn
What is the target price for Portman Ridge Finance Corporation stockInsider Selling & Real-Time Volume Spike Alerts - baoquankhu1.vn
Will Allarity Therapeutics Inc. stock recover after earningsJuly 2025 Snapshot & Risk Controlled Stock Alerts - mfd.ru
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
Aug Setups: Will Wrap Technologies Inc face regulatory challengesJuly 2025 Weekly Recap & Entry Point Confirmation Signals - baoquankhu1.vn
Allarity Therapeutics Opens Enrollment for Phase 2 Trial in Lung Cancer - TradingView
Allarity begins phase 2 trial of stenoparib combination for lung cancer - Investing.com Nigeria
Allarity Therapeutics and US Veterans Administration open enrollment for mid-stage trial of stenoparib with temozolomide in relapsed small cell lung cancer - marketscreener.com
Allarity Therapeutics announces that its collaborative Phase 2 trial with the United States Veteran’s Administration Combining Stenoparib with Temozolomide in Relapsed Small Cell Lung Cancer is Now Open for Enrollment - ChartMill
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
Can Allarity Therapeutics Inc. keep up with sector leadersJuly 2025 Weekly Recap & Intraday High Probability Alerts - baoquankhu1.vn
Published on: 2026-02-02 00:08:12 - baoquankhu1.vn
Published on: 2026-02-09 17:34:13 - baoquankhu1.vn
Can Allarity Therapeutics Inc. disrupt its industryChart Signals & Reliable Breakout Forecasts - mfd.ru
Published on: 2026-01-29 19:48:00 - mfd.ru
Allarity Therapeutics Secures Flexible Equity Financing Facility - TipRanks
Allarity Therapeutics Signs Common Stock Purchase Agreement With Tumim Stone Capital - TradingView
Activity Recap: Will Advanced Flower Capital Inc benefit from rising consumer demand2025 Performance Recap & Growth Oriented Trade Recommendations - baoquankhu1.vn
Allarity Therapeutics Inc Azioni (ALLR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.48%
1.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):